The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Inclusion Criteria:

• Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
• start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given >= 24 months ago.
• Compliance with registry procedures
• Age >= 18 years
• WHO Performance Status of 0 or 1 (Karnofsky-Index >= 70%)
• Life expectancy of at least 12 weeks
• Signed and dated informed consent before the start of the registry

Exclusion Criteria:

• Mentally incapable or incompliant patients
• Last chemotherapy <= 24 months (if pretreated)
• Known hypersensitivity to antiemetic medication
• unability of the patient to be treated with oral medication
• pregnancy or lactation period

Practitioners specialized in oncology, hematology and/or gynaecology